From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS

Time: 9:00 am
day: Day Two


  • Pursuing combination therapy to decelerate disease progression and improving QoL
  • Demonstrating therapeutic efficacy in Zebrafish to assess a synergistic combination therapy
  • The role of biomarkers in the regulatory approval process of novel therapies in ALS